Polycystic kidney disease: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• PKD1 1
• SGLT2 1
• AMPK 1
• CFTR 1
• STAT3 0
• GLP-1 1
• mTOR 0
• MUC1 0
• CDK4/6 0
• DMD 1
• EGFR 0
• G6PD 0
• HER2 0
• HTT 1
• IL-6 0
• MAPK 0
• NF1 1
• NRF2 1
• PD-L1 0
• PKM2 0
• PPAR 0
• SMN1 1
• STING 0
• TLR4 0
• TNF 0
• YAP 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 255 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Trials whose registry record says individual participant data (IPD) will be shared.

• Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney Disease

  NCT07228364· AstraZeneca· Source

• Bempedoic Acid Therapy for Polycystic Kidney Disease

  NCT07282821· Kenneth Hallows· Source

• A Study to Evaluate the Safety, Tolerability, and Effects on Blood and Urine Markers of Single Ascending Dose of GSK4771261 in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney Disease

  NCT06734234· GlaxoSmithKline· Source

• Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease

  NCT05510115· University of Colorado, Denver· Source

• Autosomal Dominant Polycystic Kidney Disease Somatic Mutation Biorepository

  NCT03901521· Weill Medical College of Cornell University· Source

• Canadian Medical Assessment of JINARC™ Outcomes Registry

  NCT02925221· Otsuka Canada Pharmaceutical Inc.· Source

• Daily Caloric Restriction in ADPKD

  NCT04907799· University of Colorado, Denver· Source

• Glucagon-Like Peptide-1 Receptor Agonist in ADPKD

  NCT06582875· University of Colorado, Denver· Source

• A Phase 3b Multicenter Open-label Trial of the Safety, Tolerability, and Efficacy of Tolvaptan in Infants and Children 28 days to less than 12 weeks of Age with Autosomal Recessive Polycystic Kidney Disease (ARPKD)

  NCT04786574· Otsuka Pharmaceutical Development & Commercialization Inc.· Source

• Study and Management of Cystic Complications in Autosomal Dominant Polycystic Kidney Disease

  NCT06036992· University Hospital, Brest· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 2
• Organoids 3
• Mendelian Randomization Analysis 1
• CRISPR-Cas Systems 7
• Gene Expression Profiling 4
• Whole Genome Sequencing 2
• Exome Sequencing 9
• Metabolomics 1
• Immunohistochemistry 1
• Magnetic Resonance Imaging 10
• Machine Learning 2
• Deep Learning 3
• Cohort Studies 12
• Genome-Wide Association Study 2

• Weighted co-expression reveals early circadian and metabolic dysregulation in precystic kidneys.

  J Mol Med (Berl), Nov 2026

• miRNA profiling of a mutation-negative PKD cohort reveals PKD1/PKD2 ADPKD shared signatures and differences.

  Epigenomics, Apr 2026

• Progressive endocannabinoid system dysregulation in autosomal dominant polycystic kidney disease.

  Mol Med, Mar 2026

• The Renal Micro-RNA Expression Profile of Pkd1RC/RC Mice Changes Longitudinally with the Progression of the Disease.

  Kidney360, Jan 2026

See which targets of this disease your abstract mentions, and go to the people working on them.